Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

According to Jinse Finance APP, TRex Bio, a biotechnology company specializing in the development of drugs for autoimmune and inflammatory diseases, filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to 100 million dollars through an initial public offering (IPO).

TRex Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that enhance the function of regulatory T cells (Treg) in inflamed human tissues, with the goal of restoring immune balance and repairing barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform can map the functional landscape of Treg cells in human skin, gut, and lung tissue to identify targets, which are then validated using proprietary in vitro Treg models and high-throughput functional assays.

Its main drug candidate, TRB-061, is a TNFR2 agonist currently in a phase 1b clinical trial for moderate-to-severe atopic dermatitis, with initial data expected to be released in mid-2027. Another wholly owned drug candidate, TRB-071, targets CD30 and is used for the treatment of inflammatory bowel disease, with phase 1 clinical trials expected to begin in the first half of 2027. Eli Lilly is both an investor and discovery partner, and is currently advancing a third candidate discovered on the platform into a phase 2a clinical trial for lupus.

This South San Francisco, California-based company was founded in 2018 and plans to list on Nasdaq with the ticker symbol “TRXB.” TRex Bio submitted its confidential listing application on June 26, 2026. JPMorgan and Evercore ISI are joint underwriters for this offering. Pricing terms have not yet been disclosed.